The Pharmaceutical Market: Peru

Date: January 31, 2013
Pages: 111
Price:
US$ 1,295.00
License [?]:
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: PB28D99865CEN
Leaflet:

Download PDF Leaflet

The Pharmaceutical Market: Peru
OVERVIEW OF THE PHARMACEUTICAL MARKET IN PERU

We have recently revised downwards our 2012 pharmaceutical sales growth for Peru, due to the recent price cuts in the prescription drug sector, which accounts for over 74% of total pharmaceutical sales. Still, our projected compound annual growth rate (CAGR) between 2011 and 2016 remains largely unchanged as BMI believes Peru still offers considerable longer-term benefits to local and foreign pharmaceutical companies because of the country's ageing population, increasing disease burden and the expected change in drug consumption patterns.

Headline Expenditure Projections

Pharmaceuticals: PEN3.90bn (US$1.42bn) in 2011 to PEN4.11bn (US$1.57bn) in 2012; +5.3% in local currency terms and +10.4% in US dollar terms. Forecast revised downwards from Q4 12 due to price cuts in the prescription drug sector.

Healthcare: PEN19.52bn (US$7.09bn) in 2011 to PEN20.73bn (US$7.90bn) in 2012; +6.2% in local currency terms and +11.4% in US dollar terms. US dollar forecast unchanged from Q4 12.

Medical devices: PEN897mn (US$326mn) in 2011 to PEN954mn (US$363mn) in 2012; +6.3% in local currency terms and +11.6% in US dollar terms. Forecast slightly lower than Q4 12 on account of macroeconomic factors.

Competitive Landscape

The Competitive Landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
EXECUTIVE SUMMARY

SWOT ANALYSIS

      Peru Pharmaceuticals And Healthcare Industry SWOT
      Peru Political SWOT
      Peru Economic SWOT
      Peru Business Environment SWOT

PHARMACEUTICAL RISK/REWARD RATINGS

      Table: Americas Pharmaceutical Risk/Reward Ratings, Q113
      Rewards
      Risks

PERU - MARKET SUMMARY

REGULATORY REGIME

      Recent Regulatory Developments
      Pharmaceutical Advertising
      OTC Medicines
      Phytotherapeutics
      Regional Harmonisation
      Intellectual Property Regime
      IP Shortcomings
      Counterfeit Pharmaceuticals
      Trade Agreements
      Pricing Regime
      Table: Peruvian Watchdog of Pharmaceutical Products (Observatorio Peruano de Productos Farmacéuticos, OPPF)
      Reimbursement Regime
      Government Tenders
      Table: Public Procurement of Pharmaceuticals by Provider, 2007-2009 (Million Soles)
      Pricing And Reimbursement Developments

INDUSTRY DEVELOPMENTS

  Epidemiology
      Table: Selected Causes of Death by Sex, 2010
  Non-Communicable Diseases
  Communicable Diseases
  Healthcare Sector
      Table: MINSA’s Decentralised Institutions & Institutes, 2011
  Healthcare Sector Developments
  Healthcare Finances
  Healthcare Provision
      Table: Infrastructure, 2004-2009
      Table: Key Goals of Parsalud II In Nine Regions
  Health Insurance
  Research and Development (R&D)
  Clinical Trials
  Medical Devices

INDUSTRY FORECAST SCENARIO

  Pharmaceutical Market Forecast
      Table: Pharmaceutical Sales Indicators 2008-2016
  Healthcare Market Forecast
      Table: Healthcare Expenditure Indicators 2008-2016
      Table: Healthcare Governmental Indicators 2008-2016
      Table: Healthcare Private Indicators 2008-2016
  Key Growth Factors – Macroeconomic
      Table: Puru Macro Indicators
  Prescription Drug Market Forecast
      Table: Prescription Drug Sales Indicators 2008-2016
  Patented Drug Market Forecast
      Table: Patented Drug Market Indicators 2008-2016
  Generic Drug Market Forecast
      Table: Generic Drug Sales Indicators 2008-2016
  OTC Medicine Market Forecast
      Table: OTC Medicine Sales Indicators 2008-2016
  Pharmaceutical Trade Forecast
      Table: Exports and Imports Indicators 2008-2016
  Medical Device Market Forecast
      Table: Medical Devices Sales Indicators 2008-2016
  Other Healthcare Data
  Key Risks To BMI's Forecast Scenario

COMPETITIVE LANDSCAPE

      Pharmaceutical Sector
      Table: Peruvian Pharmaceutical Companies That Acquired GMP Accreditation In 2006
      Table Members of ADIFAN, 2011
      Table: Members of ALAFARPE, 2011
      Table: Members of COMSALUD, 2011
      Foreign Industry
      Domestic Industry
      Table: Domestic Production, 1992-2009
      Pharmaceutical Distribution
      Pharmaceutical Retail

COMPANY PROFILES

  Domestic Companies
      Farmaindustria
      Unimed
      Hersil
  Multinational Companies
      Sanofi
      Merck & Co
      GlaxoSmithKline
      Novartis
      Pfizer
      AstraZeneca
      Teva (Corporación Medco)

DEMOGRAPHIC OUTLOOK

    Table: Peru's Population By Age Group, 1990-2020 ('000)
    Table: Peru's Population By Age Group, 1990-2020 (% of total)
    Table: Peru's Key Population Ratios, 1990-2020
    Table: Peru's Rural And Urban Population, 1990-2020

GLOSSARY

BMI METHODOLOGY

    How We Generate Our Pharmaceutical Industry Forecasts
    Pharmaceuticals Business Environment Ratings
    Risk/Reward Ratings Methodology
    Ratings Overview
    Table: Pharmaceutical Business Environment Indicators
    Weighting
    Table: Weighting Of Components
    Sources
Skip to top


The Pharmaceutical Market: Chile US$ 1,295.00 Jan, 2013 · 141 pages
The Pharmaceutical Market: China US$ 1,295.00 Jan, 2013 · 118 pages
The Pharmaceutical Market: Colombia US$ 1,295.00 Jan, 2013 · 114 pages
The Pharmaceutical Market: Croatia US$ 1,295.00 Jan, 2013 · 86 pages

Ask Your Question

The Pharmaceutical Market: Peru
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: